| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | KOBENHAVNS UNIVERSITET | NORREGADE 10 | KOBENHAVN | | | | DNK | R21AI164147 | High-throughput mapping of human antibody sequences to PfEMP1 malaria antigen specificity | 000 | 2 | NIH | 2/4/2025 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $176,108 ) |
| | 2022 | 2022 | KOBENHAVNS UNIVERSITET | NORREGADE 10 | KOBENHAVN K | | | | DNK | R21AI164147 | High-throughput mapping of human antibody sequences to PfEMP1 malaria antigen specificity | 000 | 2 | NIH | 6/21/2022 | $176,108 |
|
| Issue Date FY: 2021 ( Subtotal = $184,291 ) |
| | 2021 | 2021 | KOBENHAVNS UNIVERSITET | NORREGADE 10 | KOBENHAVN K | | | | DNK | R21AI164147 | High-throughput mapping of human antibody sequences to PfEMP1 malaria antigen specificity | 000 | 1 | NIH | 7/7/2021 | $184,291 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2015 | KOBENHAVNS UNIVERSITET | NORREGADE 10 | KOBENHAVN K | | 1165 | | DNK | U01FD005307 | Development of Predictive in vitro Methods for Characterizing Product Performance, using , Case Study: Furosemide | 001 | 2 | FDA | 1/16/2018 | $0 |
| | 2018 | 2015 | KOBENHAVNS UNIVERSITET | NORREGADE 10 | KOBENHAVN K | | 1165 | | DNK | U01FD005307 | Development of Predictive in vitro Methods for Characterizing Product Performance, using , Case Study: Furosemide | 000 | 2 | FDA | 1/12/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = -$50,000 ) |
| | 2017 | 2015 | KOBENHAVNS UNIVERSITET | NORREGADE 10 | KOBENHAVN K | | 1165 | | DNK | U01FD005307 | Development of Predictive in vitro Methods for Characterizing Product Performance, using , Case Study: Furosemide | 000 | 2 | FDA | 1/19/2017 | -$50,000 |
|
| Issue Date FY: 2016 ( Subtotal = $0 ) |
| | 2016 | 2015 | University of Copenhagen | Norregade 10 | COPENHAGEN | | 1165 | | DNK | U01FD005307 | Development of Predictive in vitro Methods for Characterizing Product Performance, using , Case Study: Furosemide | 000 | 2 | FDA | 2/8/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $50,000 ) |
| | 2015 | 2015 | University of Copenhagen | Norregade 10 | Copenhagen | | | | DNK | U01FD005307 | Development of Predictive in vitro Methods for Characterizing Product Performance, using , Case Study: Furosemide | 000 | 2 | FDA | 8/3/2015 | $50,000 |
|
| Issue Date FY: 2014 ( Subtotal = $99,895 ) |
| | 2014 | 2014 | University of Copenhagen | Norregade 10 | Copenhagen | | | | DNK | U01FD005307 | Development of Predictive in vitro Methods for Characterizing Product Performance, using , Case Study: Furosemide | 000 | 1 | FDA | 9/10/2014 | $99,895 |
|
| Issue Date FY: 2012 ( Subtotal = $25,000 ) |
| | 2012 | 2012 | UNIVERSITY OF COPENHAGEN | BLEGDAMSVEJ 3 2200 N | COPENHAGEN | | | | DNK | R03MH097598 | SMALL-MOLECULE INHIBITORS OF HADAM12 | 000 | 1 | NIH | 8/31/2012 | $25,000 |
| | 2012 | 2008 | UNIVERSITY OF COPENHAGEN | NOERREGADE 10 COPENHAGEN 1017 | COPENHAGEN | | | | DNK | F32HG004182 | THE USE OF RECOMBINING GENETIC MARKERS FOR DEMOGRAPHIC INFERENCE | 000 | 2 | NIH | 8/4/2012 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $4,872 ) |
| | 2008 | 2008 | UNIVERSITY OF COPENHAGEN | NOERREGADE 10 COPENHAGEN 1017 | COPENHAGEN | | | | DNK | F32HG004182 | THE USE OF RECOMBINING GENETIC MARKERS FOR DEMOGRAPHIC INFERENCE | 000 | 2 | NIH | 1/22/2008 | $4,872 |
|
| Issue Date FY: 2006 ( Subtotal = $36,996 ) |
| | 2006 | 2006 | UNIVERSITY OF COPENHAGEN | NOERREGADE 10 COPENHAGEN 1017 | COPENHAGEN | | | | DNK | F32HG004182 | THE USE OF RECOMBINING GENETIC MARKERS FOR DEMOGRAPHIC INFERENCE | 000 | 1 | NIH | 9/26/2006 | $36,996 |
|
|
